P116 Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program

MLA

Pellegrino Musto, et al. P116 Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes: Final Results from an Italian Named Patient Program. Jan. 2009. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1dc93b2effc4d0bae508ae30ee3e86ec&authtype=sso&custid=ns315887.

APA

Pellegrino Musto, Anna Candoni, Valeria Santini, Fortunato Morabito, Monia Lunghi, Enrico Orciuolo, Patrizio Mazza, Alessandra Spagnoli, A. Aloe Spiriti, A. D’Arco, Luca Maurillo, Adriano Venditti, Domenico Pastore, B. Pollio, & Carla Filì. (2009). P116 Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program.

Chicago

Pellegrino Musto, Anna Candoni, Valeria Santini, Fortunato Morabito, Monia Lunghi, Enrico Orciuolo, Patrizio Mazza, et al. 2009. “P116 Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes: Final Results from an Italian Named Patient Program,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....1dc93b2effc4d0bae508ae30ee3e86ec&authtype=sso&custid=ns315887.